




Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes

Taylor, P et al. Ther Adv Musculoskelet Dis. 2022 Aug 16;14:1759720X221114101

Primary goals of rheumatoid arthritis (RA) treatment:	• Reduce disease signs and symptoms • Prevent progression of joint damage • Improve physical function and quality of life
European Alliance of Associations for Rheumatology recommends:	• Treat-to-target strategy • Aim for sustained clinical remission (or low disease activity) • Change therapy if target not reached by 6 months



Therapeutic drug monitoring may assist cycling or swapping decisions	
Loss of response	May help identify patients likely to benefit from cycling strategy
High drug levels + ADAs absent	Swapping strategy
Low drug levels + ADAs high	Cycling strategy

Factors for making management decisions	Cycle	Swap			
	Anti-TNF	TsDMARD (JAKi)	IL-6Ri	B-cell depletion	Co-stim blockade
Monotherapy	Favoured	Favoured	Strongly favoured	Neutral	Neutral
Minimisation of polypharmacy	Neutral	Favoured	Favoured	Strongly favoured	Neutral
Pregnancy and lactation	Strongly favoured	Contraindicated	Contraindicated	Contraindicated	Contraindicated
Rheumatoid factor positive	Neutral	No data	Favoured	Strongly favoured	Neutral
ACPA positive	Neutral	No data	Neutral	Favoured	Favoured
IMiD	Strongly favoured	Favoured	Neutral	Favoured	Neutral
Vasculitis	Caution	Neutral	Favoured	Strongly favoured	Neutral
Uveitis	Strongly favoured	Favoured	Neutral	Favoured	Neutral
MACE	Favoured	Caution	Favoured	No data	Favoured
CV mortality	Favoured	Caution	No data	No data	No data
VTE	Neutral	Caution	Neutral	Neutral	Neutral
Heart failure	Caution	No data	No data	No data	No data
Anaemia	Favoured	Neutral	Strongly favoured	Neutral	Neutral
Type II diabetes	Neutral	Neutral	Favoured	Neutral	Neutral
Recurrent herpes zoster	Caution	Contraindicated	Neutral	Neutral	Neutral
Latent tuberculosis	Caution	Favoured	Neutral	Neutral	Neutral
Recurrent or chronic infection	Caution	Caution	Caution	Caution	Caution
Haematological tumours	Neutral	Neutral	Neutral	Strongly favoured	Neutral
Solid tumours (excluding melanoma)	Neutral	Contraindicated	Neutral	Neutral	Caution
Interstitial lung disease	Caution	Caution	Neutral	Strongly favoured	Strongly favoured
Pain	Neutral	Favoured	Favoured	Neutral	Neutral
Gastric perforation risk/diverticulitis	Neutral	Contraindicated	Contraindicated	Neutral	Neutral
Nodules	Neutral	Neutral	Neutral	Strongly favoured	Neutral
Demyelinating events and disease	Caution	Neutral	Neutral	Strongly favoured	Neutral

● No data ● Contraindicated ● Caution ● Neutral ● Favoured ● Strongly favoured

